INSULIN-LIKE GROWTH FACTOR-1, CYTOLYSIS AND CHOLESTASIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS COMBINATION WITH TYPE 2 DIABETES MELLITUS
https://doi.org/10.17650/1818-8338-2013-3-4-48-52
Abstract
Purpose. The study was designed to assess the relationship between the level of plasma concentration of insulin-like growth factor-1 (IGF-1) and indices of the functional state of the liver in patients with non-alcoholic fatty liver disease (NAFLD) and its combination with diabetes mellitus (DM) 2 types depending on the trophological status.
Materials and methods. It were examined 90 patients with non-alcoholic fatty liver disease and its combination with type 2 diabetes mellitus –
with normal body weight and obesity, as well as 20 healthy individuals. The study was carried out using the following methods: clinical, laboratory and instrumental (including liver biopsy).
Results. It was inverse the relationship between the level of IGF-1, and the level of AST, ALT, AST/ALT, total and conjugated bilirubin, alkaline phosphatase in groups of patients with comorbid disorder. There was established the significant decrease of plasma level of IGF-1, and also impairment of liver function indices in all groups in comparison with the controls, and most pronounced changes in patients with comorbid disorders and obesity.
Conclusion. The established relationships suggests that the decrease of IGF-1 may represent the presence of syndromes of cytolysis and cholestasis in patients with NAFLD, type 2 DM and obesity. In order to determination the disorder of the reparative function of the liver is
recommended to determine the level of IGF-1 in patients with combination of NAFLD and type 2 DM. Patients with the level of IGF-1 < 143,9 ± 4,92 ng/ml should refer to the risk of progression of liver function disorders.
About the Authors
L. V. Zhuravlyova
Kharkov National Medical University
Russian Federation
Russian Federation
E. V. Ogneva
Kharkov National Medical University
Russian Federation
Russian Federation
References
1. Драпкина О. М., Смирин В. А., Ивашкин В. Т. Патогенез, лечение и эпидемиология НАЖБП – что нового? Эпидемиология НАЖБП в России. РМЖ 2011;19(28):1717–21.
2. Драпкина О. М., Ивашкин В. Т. Настоящее и будущее терапии НАЖБ. Врач 2011;(7):27–31.
3. Бабак О. Я. Причины и метаболические последствия неалкогольной жировой болезни печени. Сучасна Гастроентерологія 2010;54(4):8–16.
4. Бабак О. Я., Колесникова Е. В. Роль адипокинов в развитии фиброза печени при неалкогольной жировой болезни. Сучасна гастроентерологія 2009;49(5):5–11.
5. Щекина М. И. Неалкогольная жировая болезнь печени. Consilium medicum 2009;11(8):37–9.
6. Коваль С. Н., Масляева Л. В., Резник Л. А. Взаимосвязь структурно-функциональных изменений сердца и уровня инсулиноподобного фактора роста 1 у больных гипертонической болезнью в сочетании с сахарным диабетом 2-го типа. Внутренняя медицина 2009;15(3):23–7.
7. Hagymási K., Reismann P., Rácz K., Tulassay Z. Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease. Orv Hetil 2009;150(48):2173–81.
8. Alderete T. L., Byrd-Williams C. E., Toledo-Corral C. M. et al. Relationships between IGF-1 and IGFBP-1 and adiposity in obese African-American and Latino adolescents. Obesity (Silver Spring) 2011;19(5):933–8.
9. García-Galiano D., Sánchez-Garrido M. A., Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007;17(4):493–503.
10. Succurro E., Arturi F., Grembiale A. et al. Positive association between plasma IGF1 and high-density lipoprotein cholesterol levels in adult nondiabetic subjects. Eur J Endocrinol 2010;163(1):75–80.
11. Colak Y., Senates E., Ozturk O. et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2012;24(3):255–61.
Review
For citations:
Zhuravlyova L.V., Ogneva E.V. INSULIN-LIKE GROWTH FACTOR-1, CYTOLYSIS AND CHOLESTASIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS COMBINATION WITH TYPE 2 DIABETES MELLITUS. The Clinician. 2013;7(3-4):48-52. (In Russ.) https://doi.org/10.17650/1818-8338-2013-3-4-48-52
Views:
1041
Email this article 